ARENA PHARMACEUTICALS INC (ARNA)

Common Stock

99.99  +0.06 (+0.06%)

After market: 99.99 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARNA. ARNA was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of ARNA have multiple concerns. ARNA is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ARNA has reported negative net income.
ARNA had negative earnings in 4 of the past 5 years.
In the past 5 years ARNA reported 4 times negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -78.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ARNA does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -1141511.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ARNA has more shares outstanding
The debt/assets ratio for ARNA is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 27.53 indicates that ARNA is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.05 indicates that ARNA is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 27.53
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 8.59 indicates that ARNA has no problem at all paying its short term obligations.
A Quick Ratio of 8.59 indicates that ARNA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 8.59
Quick Ratio 8.59

More info and screens

3

3. Growth

3.1 Past

ARNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.46%.
Looking at the last year, ARNA shows a very negative growth in Revenue. The Revenue has decreased by -82.00% in the last year.
ARNA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -77.43% yearly.
EPS 1Y (TTM)-19.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.81%
Revenue 1Y (TTM)-82%
Revenue growth 3Y-85.58%
Revenue growth 5Y-77.43%
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ARNA will show a decrease in Earnings Per Share. The EPS will decrease by -2.25% on average per year.
The Revenue is expected to grow by 439.46% on average over the next years. This is a very strong growth
EPS Next Y2.6%
EPS Next 2Y3.11%
EPS Next 3Y-0.06%
EPS Next 5Y-2.25%
Revenue Next Year4629.54%
Revenue Next 2Y1075.64%
Revenue Next 3Y597.1%
Revenue Next 5Y439.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.44

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.11%
EPS Next 3Y-0.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARENA PHARMACEUTICALS INC

NASDAQ:ARNA (3/10/2022, 7:10:48 PM)

After market: 99.99 0 (0%)

99.99

+0.06 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.17B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.55%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -1141511.11%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.59
Quick Ratio 8.59
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-82%
Revenue growth 3Y-85.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y